Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia
NCT06099366Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2033
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of vincristine sulfate liposome injection, asparaginase escherichia coli, dexamethasone, cytarabine, methotrexate in acute lymphoblastic leukemia (ALL). Started Mar 2024; status: recruiting.
02
Drugs
vincristine sulfate liposome injectionasparaginase escherichia colidexamethasonecytarabinemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06099366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099366.